Skip to Main Content

Paper Details

A Gene Panel Associated With Abemaciclib Utility in <i>ESR1</i>-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
JCO Precis Oncol
3
2023
Abemaciclib, Breast Cancer, CDK4, CDK4/6i, CDK4/6i resistance genes, CDKi, CDKi-R, CDKi-R mutations, CDKi-R[+], CDKi-R[-], Cyclin-Dependent Kinase 4/6, ESR1, ESR1-, ESR1-MUT, ESR1-MUT MBC, Gene Panel, HER2, HR, MBC, abemaciclib, breast cancer, circulating tumor cells, cyclin-dependent kinase 4/6, gene panel, genomic panel, hormone receptor, human epidermal growth factor receptor, human epidermal growth factor receptor 2, immortalized breast cancer cells, metastatic breast cancer, palbociclib, patient-derived circulating tumor cell lines, patients, ribociclib, tumor
Author NameAffiliation
Andrzej NiemierkoMassachusetts General Hospital Cancer Center, Harvard Medical School
Cynthia X MaWashington University School of Medicine
Anthony J IafrateMassachusetts General Hospital Cancer Center, Harvard Medical School
Nikhil WagleDana-Farber Cancer Institute, Harvard Medical School
Nikhil WagleDana-Farber Cancer Institute, Harvard Medical School
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School
  • 1 - 6

Datasets

Release 1.2